Bull of the Day: Incyte (INCY) – Bull of the Day
Incyte Corporation (INCY) is a $12 billion pharmaceutical company that is expected to finally turn a profit next year on the success of its drug Jakafi, the only FDA-approved treatment for myelofibrosis (MF). Incyte was formerly called Incyte Genomics in the 1990s when it was a pioneer in that groundbreaking research and a key provider of database information on the human genome to the world’s top pharmaceutical companies. Jakafi (ruxolitinib) has been used to treat more than 9,800 patients with MF worldwide and will represent over $350 million of the company’s $500 million in revenues for 2014 […]